Top Tweets for #HIF2
Congratulations to @KCPUTSW @UTSWHemeOnc investigators on their @CD_AACR paper https://t.co/iauTEQZM27 establishing a role for #HIF2 in PTHrP regulation and hypercalcemia in #renalcancer & @kaelin_lab in press @NatureMedicine.
Listening to some extraordinary researchers, including a @NobelPrize-winning scientist, Bill Kaelin, and the incredible @DrChoueiri here at the @DanaFarber #MedicalOncology Faculty Retreat. #HIF2 #VHL

#ASCO2025 Día 2️⃣ - #GU
#kidneycancer
La Dra. @DrRanaMcKay y su interesante update de inhibidores #HIF2 en escenario avanzado y adyuvante.
🎯 #LITESPARK trials
🔜 Nuevas fronteras en CCR: casdatifan

Powerful talk by @DrRanaMcKay with an overview on #HIF2 inhibitors treatment landscape, #LITESPARK clinical trials comprehensive results and updates. Exciting data and future opportunities for #RCC therapy armentarium.
#ASCO25 @ASCO @ASCOPost @JCO_ASCO @neerajaiims @montypal @bergsa83 @GlopesMd @VivekSubbiah @OncoAlert @tompowles1 @OncBrothers @yekeduz_emre @ZiadBakouny @AminNassarMD @NazliDizman

HIF-2 targeting is the next frontier for RCC, as VHL loss drives its overactivity; belzutifan's promising LITESPARK-005 results signal a wave of new therapies. #RCC #HIF2 #KidneyCancer | @brian_rini
https://t.co/ivc0YgpJet

Proud to have contributed to this massive work from Silvia Martin Puig lab @SMART18617738 and led by Teresa Albendea 💪.
#Vascular #HIF2 Signalling prevents #Cardiomegaly, Alveolar congestion, and Capillary Remodelling During Chronic #Hypoxia.
HIF2 signaling is necessary for the stability of heart and lung microvasculature during chronic hypoxia, preventing cardiac dysfunction and pulmonary congestion.
https://t.co/3mShLgguQy

Interesting interplay between #microbiome & #HIF2 pathways. Any implications for #kidneycancer, perhaps in the context of #belzutifan therapy? Could the effect of R. torques extend beyond the gut? Food for thought (pun intended). @mzugman @ReginaBarCar @NazliDizman @yunroseli https://t.co/pgU0BWJRSw

Appreciate your support @neerajaiims! Eager to present this data & get feedback at #ASCO24. The world of #HIF2 inhibition is ever expanding - will be good to get perspective on how we can develop novel rational combinations.
@NazliDizman @ZeynepZengin @LuisMezaco @EbrahimiHedyeh @mzugman @ReginaBarCar @PauloBergerot @crisbergerot @TDorffOnc @arafflemd @AbhiTrip87 @WesleyYipMD @yunroseli @ASCO
Ab#4513 @ASCO #ASCO24 👉https://t.co/ojEKABhpCy👉Ph1 study of DFF332, a novel oral HIF2α inhibitor, in pts w/ aRCC #kidneycancer👉promising safety profile & no grade 4 TRAEs or hypoxia reported👇Congrats @montypal @AlbigesL for the oral abst @OncoAlert @urotoday @KidneyCancer

Congratulations to the team including Nizar @MDAndersonNews @brian_rini on first #siRNA #RCC phase 1 https://t.co/psbH7od9ms with @ArrowheadPharma #HIF2 siRNA building upon https://t.co/NXPPwD7cIW (PMID36190432) opening new field.

Outstanding Distinguished Lecture @FoxChaseCancer with Dr. Bill Kaelin @DanaFarber @NobelPrize!
Great Science, Great Advice & Amazing Impact Bench-to-Bedside targeting #VHL via #HIF2 targeting in Cancer and Disease
He also suggested all checkout the QR code.
@CeiFccc

2) RCC: a lot around #HIF2 this time:
LBA87 - Phase 2 LITESPARK-003 Study of Belzutifan in Combination With Cabozantinib for Advanced Clear Cell Renal Cell Carcinoma (ccRCC) – COI: presented by @DrChoueiri (LBA)
Explore emerging #HIF2 #Hypoxic research with field leaders @KeystoneSymp Hypoxia: From Basic Mechanisms to Emerging Therapies, this May in Killarney! https://t.co/Cyish4LqnW #KSHypoxia23

Register now for On Demand Access to @KeystoneSymp #Hypoxia: Basic Mechanisms to Emerging Therapies, this May to explore emerging #HIF2 #Hypoxic research! https://t.co/t8YK92blNo #KSHypoxia23

Explore emerging #HIF2 #Hypoxic research with field leaders @KeystoneSymp #Hypoxia: Basic Mechanisms to Emerging Therapies, this May in Killarney Co. Kerry! #KSHypoxia23
https://t.co/3uFxMRbisa

Explore emerging #HIF2 #Hypoxic research with field leaders @KeystoneSymp #Hypoxia: Basic Mechanisms to Emerging Therapies, this May in Killarney Co. Kerry! #KSHypoxia23
https://t.co/3uFxMRbisa

Explore emerging #HIF2 #Hypoxic research with field leaders @KeystoneSymp #Hypoxia: Basic Mechanisms to Emerging Therapies, this May in Killarney Co. Kerry! https://t.co/NWtrodABJe #KSHypoxia23

Explore emerging #HIF2 #Hypoxic research with field leaders @KeystoneSymp #Hypoxia: Basic Mechanisms to Emerging Therapies, this May in Killarney Co. Kerry! https://t.co/Lcf9Bickeu #KSHypoxia23

Last Seen Hashtags on Sotwe
sexyCaptions
Seen from Poland
gebzeeskort
Seen from Turkey
Baited #horny
teenagee() nolimit()* filter:native_video
Seen from Italy
ReasonsToBeCreative
Seen from United States
baitrequest
Seen from Germany
DiamondJackson
Seen from India
deisygarcia
Seen from Canada
SessizYürüyenler
Seen from United Kingdom
miamalkova porn
Most Popular Users

Elon Musk 
@elonmusk
240.9M followers

Barack Obama 
@barackobama
119.2M followers

Donald J. Trump 
@realdonaldtrump
111.8M followers

Cristiano Ronaldo 
@cristiano
111.4M followers

Narendra Modi 
@narendramodi
107M followers

Rihanna 
@rihanna
97.9M followers

NASA 
@nasa
92.2M followers

Justin Bieber 
@justinbieber
91.1M followers

KATY PERRY 
@katyperry
88.1M followers

Taylor Swift 
@taylorswift13
82M followers

Lady Gaga 
@ladygaga
73.5M followers

Virat Kohli 
@imvkohli
70.6M followers

Kim Kardashian 
@kimkardashian
70M followers

YouTube 
@youtube
68.7M followers

Bill Gates 
@billgates
64.1M followers

Neymar Jr 
@neymarjr
63.4M followers

The Ellen Show
@theellenshow
62.4M followers

CNN 
@cnn
61.9M followers

Selena Gomez 
@selenagomez
61.2M followers

X 
@x
60.8M followers


























![DrChoueiri's tweet photo. 4/ For the results:
N=52 patients were allocated to cohort 2.
Median time from dose 1 ➡️ data cut-off (Feb 1 22) = 24.6 months
-ORR 31% [95CI 18·7–45·1] (16/52): 1 CR (2%) + 15PR (29%) with 92% CR/PR/SD!
-Median TTR = 3.2 months (shorter than single agent HIF-2 inh)
#HIF2 #VEGF https://t.co/H5l8qwBzWw](https://pbs.twimg.com/media/FsoOhsgXsAAsBDJ.png)
![DrChoueiri's tweet photo. 4/ For the results:
N=52 patients were allocated to cohort 2.
Median time from dose 1 ➡️ data cut-off (Feb 1 22) = 24.6 months
-ORR 31% [95CI 18·7–45·1] (16/52): 1 CR (2%) + 15PR (29%) with 92% CR/PR/SD!
-Median TTR = 3.2 months (shorter than single agent HIF-2 inh)
#HIF2 #VEGF https://t.co/H5l8qwBzWw](https://pbs.twimg.com/media/FsoODg7WAAACYKV.png)
![DrChoueiri's tweet photo. 4/ For the results:
N=52 patients were allocated to cohort 2.
Median time from dose 1 ➡️ data cut-off (Feb 1 22) = 24.6 months
-ORR 31% [95CI 18·7–45·1] (16/52): 1 CR (2%) + 15PR (29%) with 92% CR/PR/SD!
-Median TTR = 3.2 months (shorter than single agent HIF-2 inh)
#HIF2 #VEGF https://t.co/H5l8qwBzWw](https://pbs.twimg.com/media/FsoOBpaWYAMYBW4.png)

